What is Retatrutide and what receptor systems does it target?

Retatrutide (LY3437943) is a tri-agonist research peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial data published in NEJM (2023) reported roughly 17% mean body-weight reduction over 24 weeks at the highest dose studied, among the largest effects reported in obesity research.

Retatrutide (LY3437943) is a tri-agonist peptide that activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. Published phase 2 clinical trial data (NEJM, 2023) reported mean body-weight reductions of approximately 17% over 24 weeks at the highest dose studied. Preclinical work suggests the glucagon receptor component enhances lipolysis and energy expenditure relative to dual GLP-1/GIP agonists, while the GLP-1 axis provides satiety and glycemic modulation.

Source: N Engl J Med (2023) · PubMed

Retatrutide — 10mg, 99.82% purity →

Summarised from peer-reviewed literature for research reference. For laboratory research use only.